In recent sessions, MYGN stock price has displayed intraday swings exceeding 3%, a sign of active speculation ahead of its next earnings release. Market chatter indicates potential upside if guidance lifts for FY Luckily, therapeutics stocks have performed well with share prices up 18.9% on average since the latest earnings results. Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Investor focus on personalized medicine is creating tailwinds for MYGN stock price, with speculators targeting an $18.50 upside in the near term if earnings surpass projections.
